Table 2 Conventional and speckle-tracking echocardiographic parameters of normal control and diabetic patients before and after 3 months of telmisartan treatment
Normal control (n = 10) | Baseline (n = 15) | After telmisartan (n = 15) | p value | |
|---|---|---|---|---|
LVMI (g/m2) | 83.3 ± 29.1 | 84.5 ± 29.8 | 85.1 ± 30.2 | 0.63 |
LVIDd (cm) | 4.2 ± 0.8 | 4.1 ± 0.7 | 4.1 ± 1.4 | 0.52 |
LVEF (%) | 70.5 ± 6.4 | 68.1 ± 4.5 | 69.3 ± 15.7 | 0.38 |
E (cm/s) | 76.5 ± 18.3 | 79.5 ± 12.3 | 82.7 ± 18.3 | 0.72 |
E/A | 1.0 ± 0.3 | 1.0 ± 0.2 | 0.9 ± 0.6 | 0.06 |
e′ (cm/s) | 10.3 ± 2.8 | 8.2 ± 1.8 | 9.3 ± 2.7 | 0.01 |
IVRT (ms) | 94.7 ± 23 | 96.6 ± 13.1 | 90.7 ± 21.5 | 0.06 |
DT (ms) | 200.5 ± 58.6 | 184.1 ± 52.2 | 198.4 ± 43.7 | 0.93 |
MPI | 0.4 ± 0.2 | 0.5 ± 0.1 | 0.5 ± 0.1 | 0.35 |
GLS (%) | −20.2 ± 6.7 | −16.4 ± 5.2 | −18.1 ± 6.2 | 0.03 |
GCS (%) | −22.2 ± 7.8 | −14.7 ± 8.6 | −20.8 ± 6.8 | 0.01 |